Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Proton who wrote (11525)	11/20/1997 2:08:00 AM
From: Proton	Respond to of 32384

Re: More on Prandin From a Reuters writeup (fair-use excerpts follow): Prandin, made by Danish biotechnology group Novo Nordisk is the first of a whole new class of drugs that affect insulin, but only briefly. The idea is to give diabetics more precise control of insulin levels...The drug, known generically as repaglinide, was co-developed with Boehringer Ingelheim GmBH and is receiving fast-track review by the FDA because it shows promise... because only 1,000 patients were studied for a year, panelists weren't convinced that hypoglycemia might not occur with more frequency once the drug is in use. The company said it is designing a study to definitively measure hypoglycemia. Nice writeup by Alicia Ault of Reuters, BTW. Really clear overview of the panel's views and the Prandin's overall market position: dljdirect.com This helped answer some of my prior questions, but I appreciate any other insights. Pý p.s. This is the way for a pharm to play Nat'l Diabetes Month!